MYND — MYND Life Sciences Cashflow Statement
0.000.00%
- CA$3.35m
- CA$6.35m
- 18
- 37
- 69
- 36
Annual cashflow statement for MYND Life Sciences, fiscal year end - October 31st, CAD millions except per share, conversion factor applied.
2020 October 31st | 2021 October 31st | 2022 October 31st | 2023 October 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Net Income/Starting Line | -0.056 | -4.37 | -3.57 | -1.52 |
Depreciation | ||||
Deferred Taxes | ||||
Non-Cash Items | 0 | 1.68 | 0.599 | -0.451 |
Unusual Items | ||||
Other Non-Cash Items | ||||
Changes in Working Capital | 0.054 | -0.213 | 1.22 | 1.75 |
Change in Accounts Receivable | ||||
Change in Other Assets | ||||
Change in Payable / Accrued Expenses | ||||
Cash from Operating Activities | -0.003 | -2.98 | -1.82 | -0.198 |
Capital Expenditures | — | -0.044 | — | — |
Purchase of Fixed Assets | ||||
Other Investing Cash Flow Items | 0 | 2.17 | -0.08 | 0.198 |
Sale of Business | ||||
Sale of Fixed Assets | ||||
Other Investing Cash Flow | ||||
Cash from Investing Activities | 0 | 2.13 | -0.08 | 0.198 |
Net Issuance / Retirement of Stock | ||||
Net Issuance / Retirement of Debt | ||||
Cash from Financing Activities | 0.003 | 2.75 | 0 | — |
Beginning Cash Balance | ||||
Ending Cash Balance | ||||
Net Change in Cash | 0 | 1.9 | -1.9 | -0 |